Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes

Summary

The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration once daily in multi-center, randomized, double-blind, placebo-controlled, parallel assignment manner.

Timeline

Start

2008-01

Primary completion

2008-12

Completion

2009-01

Drugs

Indications